乳腺癌的异质性。
Heterogeneity in breast cancer.
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
出版信息
J Clin Invest. 2011 Oct;121(10):3786-8. doi: 10.1172/JCI60534. Epub 2011 Oct 3.
Abstract
Breast cancer is a heterogeneous disease. There is a high degree of diversity between and within tumors as well as among cancer-bearing individuals, and all of these factors together determine the risk of disease progression and therapeutic resistance. Advances in technologies such as whole-genome sequencing and functional viability screens now allow us to analyze tumors at unprecedented depths. However, translating this increasing knowledge into clinical practice remains a challenge in part due to tumor evolution driven by the diversity of cancer cell populations and their microenvironment. The articles in this Review series discuss recent advances in our understanding of breast tumor heterogeneity, therapies tailored based on this knowledge, and future ways of assessing and treating heterogeneous tumors.
摘要
乳腺癌是一种异质性疾病。肿瘤之间、肿瘤内部以及携带肿瘤的个体之间存在高度的多样性，所有这些因素共同决定了疾病进展和治疗耐药的风险。全基因组测序和功能活性筛选等技术的进步现在使我们能够以前所未有的深度分析肿瘤。然而，将这些不断增加的知识转化为临床实践仍然是一个挑战，部分原因是癌症细胞群体及其微环境的多样性驱动了肿瘤的进化。本综述系列中的文章讨论了我们对乳腺癌异质性的理解的最新进展、基于这些知识定制的治疗方法，以及评估和治疗异质性肿瘤的未来方法。
相似文献
1
Heterogeneity in breast cancer.
J Clin Invest. 2011 Oct;121(10):3786-8. doi: 10.1172/JCI60534. Epub 2011 Oct 3.
2
Breast cancer: origins and evolution.
J Clin Invest. 2007 Nov;117(11):3155-63. doi: 10.1172/JCI33295.
3
Intratumor Heterogeneity in Breast Cancer.
Adv Exp Med Biol. 2016;882:169-89. doi: 10.1007/978-3-319-22909-6_7.
4
The Dawning of Translational Breast Cancer: From Bench to Bedside.
Adv Exp Med Biol. 2017;1026:1-25. doi: 10.1007/978-981-10-6020-5_1.
5
Advances in Tumor Sampling and Sequencing in Breast Cancer and their Application in Precision Diagnostics and Therapeutics.
Adv Exp Med Biol. 2021;1187:215-244. doi: 10.1007/978-981-32-9620-6_11.
6
Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies.
Semin Cancer Biol. 2022 Jul;82:3-10. doi: 10.1016/j.semcancer.2021.07.010. Epub 2021 Jul 16.
7
Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer.
Am Soc Clin Oncol Educ Book. 2018 May 23;38:56-64. doi: 10.1200/EDBK_200731.
8
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493.
9
Heterogeneity of breast cancer: etiology and clinical relevance.
Clin Transl Oncol. 2011 Nov;13(11):767-73. doi: 10.1007/s12094-011-0731-9.
10
Breast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities.
Rev Invest Clin. 2017 Mar-Apr;69(2):66-76. doi: 10.24875/ric.17002177.
引用本文的文献
1
A Validated Proteomic Signature of Basal-like Triple-Negative Breast Cancer Subtypes Obtained from Publicly Available Data.
Cancers (Basel). 2025 Aug 8;17(16):2601. doi: 10.3390/cancers17162601.
2
Evolution and integration of artificial intelligence across the cancer continuum in women: advances in risk assessment, prevention, and early detection.
Cancer Causes Control. 2025 Aug 20. doi: 10.1007/s10552-025-02048-6.
3
Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence.
Sci Prog. 2025 Jul-Sep;108(3):368504251362350. doi: 10.1177/00368504251362350. Epub 2025 Aug 19.
4
Induction of ER stress-mediated apoptosis in breast cancer cell line by the powerful alkylating agent bendamustine and insights into its molecular mechanisms.
Med Oncol. 2025 Aug 8;42(9):416. doi: 10.1007/s12032-025-02981-1.
5
5-(Thiophen-2-yl)isoxazoles as novel anti-breast cancer agents targeting ERα: synthesis, biological evaluation, studies, and molecular dynamics simulation.
RSC Med Chem. 2025 Jun 25. doi: 10.1039/d5md00339c.
6
A benchmarking study of copy number variation inference methods using single-cell RNA-sequencing data.
Precis Clin Med. 2025 Jun 4;8(2):pbaf011. doi: 10.1093/pcmedi/pbaf011. eCollection 2025 Jun.
7
Identification and validation of synergistic drug strategies targeting macrophage polarization in triple-negative breast cancer via single-cell transcriptomics and deep learning.
Transl Oncol. 2025 Jun 26;59:102457. doi: 10.1016/j.tranon.2025.102457.
8
Lobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β-Catenin Signaling Pathway in MCF-7 Cells.
Pharmacol Res Perspect. 2025 Aug;13(4):e70142. doi: 10.1002/prp2.70142.
9
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer.
J Clin Invest. 2025 Jun 10;135(15). doi: 10.1172/JCI186599. eCollection 2025 Aug 1.
10
The Use of Mutational Signatures to Decipher the Inter-Relationship of Reactive Oxygen Species with Homologous Recombination and Non-Homologous End-Joining Deficiencies as Well as Their Effects on APOBEC Mutagenesis in Breast Cancer.
Cancers (Basel). 2025 May 12;17(10):1627. doi: 10.3390/cancers17101627.
本文引用的文献
1
Insight into the heterogeneity of breast cancer through next-generation sequencing.
J Clin Invest. 2011 Oct;121(10):3810-8. doi: 10.1172/JCI57088. Epub 2011 Oct 3.
2
Breast cancer stem cells, cytokine networks, and the tumor microenvironment.
J Clin Invest. 2011 Oct;121(10):3804-9. doi: 10.1172/JCI57099. Epub 2011 Oct 3.
3
Targeted therapies for breast cancer.
J Clin Invest. 2011 Oct;121(10):3797-803. doi: 10.1172/JCI57152. Epub 2011 Oct 3.
4
Breast cancer - one term, many entities?
J Clin Invest. 2011 Oct;121(10):3789-96. doi: 10.1172/JCI57100. Epub 2011 Oct 3.
5
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.
6
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
J Clin Invest. 2011 Jul;121(7):2723-35. doi: 10.1172/JCI44745.
7
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state.
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7950-5. doi: 10.1073/pnas.1102454108. Epub 2011 Apr 15.
8
Tumour evolution inferred by single-cell sequencing.
Nature. 2011 Apr 7;472(7341):90-4. doi: 10.1038/nature09807. Epub 2011 Mar 13.
9
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.
Cell Stem Cell. 2011 Feb 4;8(2):149-63. doi: 10.1016/j.stem.2010.12.007.
10
Breast cancer management: opportunities and barriers to an individualized approach.
Oncologist. 2011;16 Suppl 1:20-2. doi: 10.1634/theoncologist.2011-S1-20.
Zotero 插件